2nd Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain, including support for the Drug Shortage Prevention and Mitigation Act. Issues related to COVID-19 response and post-public health emergency recommendations, including telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided vaccinations for COVID/flu/pediatric illnesses, COVID-19 testing, emergency HIV prophylaxis, initiation of oral antivirals for flu/COVID, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Patient access to comprehensive reproductive healthcare (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Lower Costs, More Transparency Act (H.R. 5378) and the Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869), provisions related to site neutral payments. The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 7153/S. 3679), provisions related to supporting health workers mental health and well-being. Issues related to the Change Healthcare cyberattack, including communications with the Department of Health and Human Services and the Centers for Medicare & Medicaid Services encouraging flexibility following the cyberattack (generally, no specific legislation). Issues related to oversight of laboratory-developed tests (generally, no specific legislation). Issues related to overtime pay requirements for healthcare workers (generally, no specific legislation).

LobbyistCovered position, as disclosed
FRANK KOLB New —
THOMAS KRAUS —
JILLANNE SCHULTE —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office

Bills named: S. 1869 (118th), S. 3679 (118th), H.R. 5378 (118th), H.R. 7153 (118th)

Medicare/Medicaid MMM

The Equitable Community Access to Pharmacist Services Act (H.R. 1770/S. 2477) and the Pharmacy and Medically Underserved Areas Enhancement Act (S. 1491), provisions related to Medicare coverage for all PREP Act services and COVID-19 response recommendations, including Medicaid reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation). Issues related to continuation of Public Readiness and Emergency Preparedness Act (PREP Act) allowances (generally, no specific legislation). Issues related to National Coverage Determination for pre-exposure prophylaxis (PrEP) for HIV prevention that would shift coverage of these services from Medicare Part D to Part B (generally, no specific legislation).

LobbyistCovered position, as disclosed
FRANK KOLB New —
THOMAS KRAUS —
JILLANNE SCHULTE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1770 (118th), S. 1491 (118th), S. 2477 (118th)

Pharmacy PHA

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to 340B Drug Pricing Program nondiscrimination and contract pharmacy arrangements, including support for the follow bills: The PROTECT 340B Act (H.R. 2534) and the 340B Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act of 2024 (H.R. 7635). Issues related to pharmacy residency funding (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to authorization of technician product verification (generally, no specific legislation). The Biosimilar Red Tape Elimination Act (S. 2305), issues related to accelerating biosimilar adoption.

LobbyistCovered position, as disclosed
FRANK KOLB New —
THOMAS KRAUS —
JILLANNE SCHULTE —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); SENATE; Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES

Bills named: S. 2305 (118th), H.R. 7635 (118th), H.R. 2534 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.